All data that was collected for this study belongs to the HUNT research center, The Faculty of medicine at NTNU, Norway. All institutions with research expertise can apply for access to analyse HUNT data. Projects must have recommendations from The Regional Committee for Medical Research in Norway (REK) and be registered with The Norwegian Social Science Data Services (NSD). The project leader affiliated with The Medical Faculty at NTNU is covered under HUNT\'s licence from The Data Inspectorate, but must obtain a recommendation from the Regional Committee for Medical and Health Research Ethics (REK). HUNT Research Centre wishes that the Principal Investigator is affiliated with a Norwegian research institute. The participant consent requires that all projects are submitted to and approved by one of the Norwegian regional ethics committees. Data that are combined with data from other registries may not be exported. These are legal requirements. Use of HUNT data or biological material in a specific project depends on approval by both the Regional Ethical Committee (REC) and Data Access Committee for HUNT Research Centre (DAC). Researchers enter into an agreement for the use of data based on the project's protocol and data request. Agreements include the titles of planned publications and a time frame after which the data must be deleted by the researcher. Participants in The HUNT Study have given a broad consent when entering into the study, agreeing to be included in studies unspecified at the time, under the condition that these are approved of by REC. If other researchers would be able to conduct new analyses on the basis of data stored in a public repository, this would be a breach of our agreement with the participants in HUNT, because the project would not be approved by an ethical committee first. REC conditions do not allow for project-related data to be stored indefinitely. HUNT data are updated by quality assurance and by participants withdrawing their consent for further analyses of data or use of biologic material. Old data files can therefore get outdated and may include participants who have expressed a wish to withdraw. <https://www.ntnu.edu/hunt>.

Introduction {#sec005}
============

Smoking tobacco is a core risk factor for cardiovascular disease (CVD) \[[@pone.0160205.ref001]--[@pone.0160205.ref004]\]. In the last 30 years the consumption has decreased significantly in Norway \[[@pone.0160205.ref005],[@pone.0160205.ref006]\]. However, the use of oral tobacco ("snuff") has been rising, especially in younger age groups \[[@pone.0160205.ref007]\]. This observation has prompted a debate about long-term consequences and whether it is safe to recommend snuff as an alternative to smoking tobacco. Most studies reporting associations between tobacco use and future cardiovascular disease have focused on long-term endpoints like heart failure, ischemic heart disease, stroke, and mortality, which are less prevalent at younger age groups and requires several years of follow-up \[[@pone.0160205.ref008]\].

Endothelial dysfunction is an early marker of atherosclerosis associated with conventional risk factors for coronary heart disease including cigarette smoking. It is also a typical finding in peripheral artery disease \[[@pone.0160205.ref009]--[@pone.0160205.ref012]\]. Therefore, assessment of endothelial function measured as flow mediated dilatation (FMD) of the brachial artery may be a useful method to detect persons with increased cardiovascular risk \[[@pone.0160205.ref013]--[@pone.0160205.ref016]\]. FMD is positively associated with physical activity \[[@pone.0160205.ref017],[@pone.0160205.ref018]\] and negatively associated with age \[[@pone.0160205.ref019]\]. Vascular endothelial cells are adversely affected by smoking tobacco \[[@pone.0160205.ref020],[@pone.0160205.ref021]\], and some studies have indicated impaired endothelial function after snuff use \[[@pone.0160205.ref022],[@pone.0160205.ref023]\]. However, these studies were either performed in oral mucosa \[[@pone.0160205.ref024]\] or with a low number of as few as 20 study-participants \[[@pone.0160205.ref024],[@pone.0160205.ref025]\]. There is some evidence that snuff aggravates the risk of cancer \[[@pone.0160205.ref026]\], but somewhat equivocal findings whether it induces atherosclerosis and enhances the risk for cardiovascular disease \[[@pone.0160205.ref027]--[@pone.0160205.ref031]\]. An accumulating number of studies show associations between use of oral tobacco products and the risk of fatal myocardial infarction and stroke \[[@pone.0160205.ref032]--[@pone.0160205.ref035]\]. Metabolic syndrome has been associated with use of snuff \[[@pone.0160205.ref036],[@pone.0160205.ref037]\], and in Norway pregnant women are recommended to refrain from using snuff because of higher risk for preeclampsia, which is associated with endothelial dysfunction and preterm birth \[[@pone.0160205.ref038],[@pone.0160205.ref039]\]. Given the incomplete knowledge of long-term effects on endothelial function, we conducted a population-based study to determine the association between the use of snuff and endothelial function measured by FMD.

Study Population {#sec006}
================

Inclusion and Exclusion {#sec007}
-----------------------

In Nord-Trøndelag County, all inhabitants from 20 years of age and up (n = 94 194) were invited to participate in the third wave of the Nord-Trøndelag Health Study (HUNT3), which was carried out between October 2006 and June 2008 \[[@pone.0160205.ref040]\]. Among the 50 821 who attended (54%), 30 588 were defined as healthy, based on a self-administered questionnaire (Q1\[[@pone.0160205.ref041]\]). From those defined as healthy, a random sample of 12 609 were invited to participate in the HUNT Fitness Study, a sub-study conducted in four selected municipalities within the county. Inclusion criteria were participation in HUNT3 and written informed consent. Besides FMD, the Fitness Study included peak oxygen uptake (VO~2peak~) measured by ergospirometry, a questionnaire assessing physical activity, and a clinical examination\[[@pone.0160205.ref042]\]. FMD from the Fitness Study was combined with data from the main HUNT Study, including questionnaire information regarding present tobacco use \[[@pone.0160205.ref043]\] and physical activity \[[@pone.0160205.ref043]\], anthropometric variables, blood pressure and serum lipids, and with socioeconomic data from Statistics Norway. Participation was voluntary and 5 633 accepted the invitation for FMD testing.

Exclusion criteria were wheezing or dyspnea during the past 12 months, previous asthma, chronic obstructive pulmonary disease, sarcoidosis, cancer, cardiovascular disease, including cerebral and peripheral arterial disease, angina and previous myocardial infarction, contraindications towards physical activity, and the use of antihypertensiva or vasoactive medication known to influence endothelial function. Respondents with arrhythmias, including atrial fibrillation and ventricular bigeminy during testing were excluded. In total, 2 211 men and 2 528 women completed FMD measurements. Since only 6 women used snuff daily, further analyses were performed on men only. Health characteristics of these men is described in details in a previous study \[[@pone.0160205.ref044]\]. Participants with inconclusive answers regarding earlier use or non-use of any kind of tobacco were excluded from analysis. After excluding respondents with missing data 1 592 men remained.

Characteristics of Background Population {#sec008}
----------------------------------------

Socio-economic status, disease epidemiology and risk factors of the study population have previously been described \[[@pone.0160205.ref006],[@pone.0160205.ref007],[@pone.0160205.ref015],[@pone.0160205.ref019],[@pone.0160205.ref045]\], and the respondents are representative of the general healthy Norwegian population \[[@pone.0160205.ref045],[@pone.0160205.ref046]\]. In Norway 14% of men in the age group 16--74 years report daily smoking and 16% use snuff daily. The proportion of occasional snuff users amongst men is 6% \[[@pone.0160205.ref007]\]. There is little variation among snuff brands in Norway; all are produced in Sweden by a heating process \[[@pone.0160205.ref047]\], and the level of nitrosamine is reportedly 0.5--3.1 micrograms per kilogram \[[@pone.0160205.ref048]\].

Methods {#sec009}
=======

Flow Mediated Dilatation {#sec010}
------------------------

Flow-mediated dilation (FMD) of the left brachial artery was measured with ultrasound and Doppler (Vivid I, GE Healthcare, USA) using a high-resolution 12 MHz array transducer (Vivid, GE Healthcare, USA). A blood pressure cuff was placed on the forearm \[[@pone.0160205.ref049],[@pone.0160205.ref050]\] with the participants in supine position in a dark and quiet room with a stable temperature. Blood flow was recorded by pulsed Doppler velocity signals. The artery was imaged at baseline after ten minutes of supine rest, and 60 seconds after cuff deflation following arterial occlusion at 250 mm Hg for five minutes. The mean of three consecutive arterial measurements was recorded using 0.1-mm resolution calipers. Diameter was measured from intima to intima at the peak of the R-wave to avoid confounding by cyclic changes in arterial dimension. FMD was defined as percent change in vessel diameter, calculated as \[(post occlusion diameter--baseline diameter) / baseline diameter\]. Inter-observer analysis with Pitman\'s Test of difference in variance ranged from r = 0.008 (n = 81, p = 0.942) to: r = -0.846 (n = 82, p = 0.000) \[[@pone.0160205.ref045]\]. Endothelial dysfunction (ED) was defined as FMD ≤ 0%. All participants received written information beforehand and were asked to fast and refrain from coffee and tobacco the last four hours before testing. Testing was part of the present cross-sectional health survey and there exist no measurements on FMD prior to recruitment in study.

Blood Pressure, Anthropometrics and Blood Analyses {#sec011}
--------------------------------------------------

Resting heart rate was recorded as the lowest heart rate during supine rest for 10 minutes. Blood pressure was measured (Critikon Dinamap 845XT, GE Medical Systems, USA), sitting according to guidelines \[[@pone.0160205.ref051]\]. Combined scales (Model DS-102, Artic Heating AS, and Norway) measured height and weight to the nearest cm and kilogram, and body mass index (BMI) was calculated. Waist circumference was measured at the umbilical level. Blood samples were drawn right after blood pressure measurements, and then centrifuged and refrigerated before transportation to the analysis laboratory on the same day. Serum analyses were performed in fresh samples. All analyses were performed by photometric methods on an Architect ci8200 (Abbott Laboratories, IL, USA). The coefficients of variation at the laboratory were 1.4--1.7% for glucose, 1.1--1.3% for cholesterol and 1.0--1.7% for high-density lipoprotein cholesterol. Peak oxygen uptake (VO~2peak~) was measured by ergospirometry during treadmill running or walking until exhaustion \[[@pone.0160205.ref052]\]. Physical activity was evaluated by a previously published index score and categorized according to current recommendations \[[@pone.0160205.ref053]\].

Confounders {#sec012}
-----------

Regression models adjusted for potential confounders; such as age, education, income, physical activity, and systolic blood pressure. Previous studies have shown that physical activity has an effect on endothelial function (FMD) \[[@pone.0160205.ref054],[@pone.0160205.ref055]\]. In Norway, snuff use is more prevalent in young men than in other groups of the population \[[@pone.0160205.ref007]\]. There is an inverse association between FMD and age \[[@pone.0160205.ref019]\]. Population studies have shown that low-income and low-educated participants have higher risk of cardiovascular disease \[[@pone.0160205.ref056]\] \[[@pone.0160205.ref044],[@pone.0160205.ref057],[@pone.0160205.ref058]\] as well as higher prevalence of other outcomes \[[@pone.0160205.ref059]\]. Systolic blood pressure is related to cardiovascular outcome and risks of cardiovascular disease \[[@pone.0160205.ref060]\]. In a previous study of the HUNT-population, we found an inverse association between systolic blood pressure (SBP) and endothelial function measured by FMD \[[@pone.0160205.ref061]\]. Further analysis revealed that the effect from tobacco on FMD was not associated with SBP (data not shown), and SBP was therefore not included in final models.

There were no differences in BMI between the tobacco-groups and non-user group ([Table 1](#pone.0160205.t001){ref-type="table"}), and there was no association in our study population between FMD and BMI, waistline, or waist-hip-ratio. This has been described in our previous study \[[@pone.0160205.ref061]\]. These variables were therefore not included as confounders in the final models.

10.1371/journal.pone.0160205.t001

###### Anthropometric data, risk factors and present tobacco use of study population.

![](pone.0160205.t001){#pone.0160205.t001g}

                                                         Non-user   Snuff, no smoke   Smoke, no snuff   Smoke and snuff                              
  ------------------------------------------------------ ---------- ----------------- ----------------- ----------------- ------ ------------ ------ --------------
  **Age, years**                                         47.4       46.8--47.9        42.8              42.0--43.7        47.4   46.7--48.1   47.4   44.0--50.8
  **Systolic BP, mmHg**                                  131        131--132          131               130--132          132    131--133     134    129.7--137.3
  **Diastolic BP, mmHg**                                 76         75--76            76                75--77            76     76--77       77     75--80
  **Waist circumference, cm**                            95.0       94.6--95.4        95.0              94.3--95.7        95.1   94.6--95.6   96.6   94.3--98.9
  **Body mass index**                                    26.4       26.2--26.6        26.7              26.3--27.1        26.4   26.0--26.7   26.3   24.8--27.9
  **Non-fasting glucose, mmol/L**^**-1**^                5.48       5.42--5.55        5.35              5.27--5.42        5.54   5.46--5.62   5.62   5.32--5.93
  **HDL-Cholesterol, mmol/L**^**-1**^                    1.21       1.20--1.22        1.23              1.21--1.25        1.19   1.18--1.21   1.17   1.09--1.24
  **Total-Cholesterol, mmol/L**^**-1**^                  5.38       5.34--5.42        5.35              5.28--5.43        5.50   5.44--5.55   5.54   5.30--5.78
  **Triglycerides, mmol/L**^**-1**^                      1.75       1.71--1.80        1.78              1.69--1.86        1.92   1.85--1.98   2.05   1.75--2.35
  **VO**~**2peak,**~ **mL·kg**^**-1**^**·min**^**-1**^   46.0       45.41--46.6       47.3              46.2--48.5        42.9   42.1--43.7   40.8   37.3--44.3
  **Physical Activity Index**                            3.4        3.2--3.6          3.5               3.1--4.0          2.5    2.3--2.8     2.0    0.8--3.1
  **Metabolic Syndrome (%)**                             17.8                         14.9                                21.9                25.4   
  **Education, years**                                   13.7       13.6--13.8        13.6              13.4--13.8        12.6   12.5--12.8   12.3   11.7--12.9
  **Income, 1000 NOK**                                   447        437--457          436               420--453          396    386--406     386    347--424

BP: blood pressure; HDL: high density lipoprotein, VO2peak: peak oxygen uptake; Income: average income 2007--2009

Approvals {#sec013}
---------

The Regional Committee for Medical and Health Research Ethics, the Norwegian Data Inspectorate and the Ministry of Health and Care Services, and Data Access Committee for HUNT Research Centre (DAC) approved of the HUNT3 study and the Fitness study. The Study Protocols conformed to the Helsinki declaration. Written informed consent was obtained from all participants.

Restrictions in Use of HUNT-Data {#sec014}
--------------------------------

Access to the requested HUNT data is given after the application is processed and a contract is signed. The contract gives the researcher(s) the right to investigate a specific topic for a limited time period and to publish a specified number of articles \[[@pone.0160205.ref062]\]. Participants in The HUNT Study have given a broad consent when entering into the study, agreeing to be included in studies unspecified at the time, under the condition that these are approved of by the Regional Ethics Committee. Each and every study conducted on HUNT data must therefore be approved of by a Norwegian Ethics Committee.

HUNT data are updated by quality assurance and with respect to participants withdrawing their consent for further analyses of data or use of biologic material. Old data files can therefore get outdated and may include participants who have expressed a wish to withdraw. Data cannot be stored in a public repository, as this would be a breach of the agreement with the participants in HUNT.

Statistical Analysis {#sec015}
--------------------

The study sample was divided into four groups based on self-reported present tobacco consumption; 1) no smoking or use of snuff at present, 2) use of snuff only, 3) smoking only, and 4) present smoking and use of snuff ([Table 1](#pone.0160205.t001){ref-type="table"}). Descriptive data are given as means and 95% confidence intervals (CI) for continuous variables, and as percentage for dichotomous variables. The precision of the estimated means, mean differences and odds ratios are presented as 95% confidence intervals (in brackets). All data were examined for missing values and unlikely outliers. A general linear model with simple contrast and FMD as the dependent variable, and tobacco use as the categorical independent variables was applied to detect differences in endothelial function. Potential confounding variables were subsequently entered as covariates in different models. Model 1 was adjusted for age; model 2 was additionally adjusted for education and income, and model 3 also included the physical activity index \[[@pone.0160205.ref063]\]. Effect modification by age and physical activity was tested formally by inclusion of interaction terms. In subsequent analyses, tobacco status was combined with self-reported physical activity level or VO~2peak~ entered as categorical independent variable. The highest level of physical activity/VO~2peak~ with no tobacco use was set as reference category. High ("fit") and low ("low fit") VO~2peak~ were defined as above and below the average value for the respective 10-year age categories, respectively. Recommended physical activity ("active") was set according to current national and international guidelines of \>75 minutes of high intensity and/or \>150 minutes of moderate intensity per week \[[@pone.0160205.ref064]\]. All statistical analyses were performed using SPSS software version18.

Results {#sec016}
=======

Tobacco Use {#sec017}
-----------

In total, 447 (28.1%) men in the main analysis reported present smoking, 238 (14.9%) use of snuff, 21 (1.3%) smoking and snuff, and 886 (55.7%) no snuff or smoking ([Table 1](#pone.0160205.t001){ref-type="table"}). Snuff users were younger than the average study population and younger than smokers ([Table 1](#pone.0160205.t001){ref-type="table"}). Snuff users had higher education, income, physical activity level and VO2peak, as well as better cardiovascular risk profile (lower blood glucose, higher HDL-cholesterol and lower total cholesterol and triglycerides) compared to smokers ([Table 1](#pone.0160205.t001){ref-type="table"}), but not compared to non-users ([Table 1](#pone.0160205.t001){ref-type="table"}).

Endothelial Function {#sec018}
--------------------

After adjustment for potential confounders, flow mediated dilation (FMD) tended to be lower in snuff users (difference: -0.53%, -1.09, 0.02) than in the non-user group ([Table 2](#pone.0160205.t002){ref-type="table"}). This difference was even more pronounced in the inactive snuff users (-0.83%, -1.59, -0.06, [Table 3](#pone.0160205.t003){ref-type="table"}) and in the low fit snuff users (-0.74%, CI -0.55, 0.07, [Table 4](#pone.0160205.t004){ref-type="table"}), respectively, compared to active or high fit participants that reported no tobacco use. Snuff users meeting current recommendations for physical activity level did not have lower FMD compared to the reference group (-0.29%, -1.25, 0.68), neither did the fit snuff users (-0.19%, -0.96, 0.57, [Table 4](#pone.0160205.t004){ref-type="table"}). There was no difference between the reference group and the active smoking tobacco users (-0.41%, -1.35, 0.53) or inactive smoking tobacco users (-0.29%, -0.91, 0.33, [Table 3](#pone.0160205.t003){ref-type="table"}). Formal tests of interaction were not significant for tobacco groups and physical activity recommendations (p = 0.56) or age (p = 0.93), respectively.

10.1371/journal.pone.0160205.t002

###### Flow mediated dilation (%) according to present snuff-use and smoking.

![](pone.0160205.t002){#pone.0160205.t002g}

                                                  Unadjusted   Model 1        Model 2   Model 3                                          
  ----------------------------------------- ----- ------------ -------------- --------- ---------------- ------- --------------- ------- ---------------
  **Non-user**                              886   4.52         (4.27, 4.78)   Ref.      \-               Ref.    \-              Ref.    \-
  **Snuff, no smoke**                       238   4.12         (3.63, 4.61)   -0.57     (-1.12, -0.01)   -0.54   (-1.09, 0.02)   -0.53   (-1.09, 0.02)
  **Present smoke, no snuff**               447   4.33         (3.97, 4.68)   -0.23     (-0.66, 0.21)    -0.17   (-0.62, 0.27)   -0.14   (-0.59, 0.31)
  **Present use of both smoke and snuff**   21    3.51         (1.86, 5.15)   -1.03     (-2.68, -0.63)   -0.99   (-2.65, 0.67)   -0.93   (-2.60, 0.73)

Model 1: adjusted for age; Model 2: adjusted for age, education and income; Model 3: adjusted for age, education, income and PAI; N: number of participants; FMD: Flow mediated dilation, %; 95% CI: 95% confidence interval; PAI: Physical activity index, Ref.; Reference group

10.1371/journal.pone.0160205.t003

###### Flow mediated dilation according to tobacco use and physical activity.

![](pone.0160205.t003){#pone.0160205.t003g}

                          N     Unadjusted   Model 1   Model 2                                     
  ----------------------- ----- ------------ --------- -------------- ------------- -------------- -------------
  **No smoke or snuff**   Yes   258          4.68      Ref.           Ref.          Ref.           Ref.
  No                      621   4.45         -0.17     -0.72, 0.39    -0.16         -0.73, 0.40    
  **Smokers**             Yes   87           4.23      -0.56          -1.49, 0.37   -0.41          -1.35, 0.53
  No                      379   4.30         -0.33     -0.94, 0.28    -0.29         -0.91, 0.33    
  **Snuff users**         Yes   82           4.52      -0.35          -1.31, 0.61   -0.29          -1.25, 0.68
  No                      156   3.90         -0.85     -1.61, -0.08   -0.83         -1.59, -0.06   

Model 1: adjusted for age; Model 2: adjusted for age, education and income; N: number of participants; FMD: Flow mediated dilation, %; 95% CI: 95% confidence interval, Ref.; Reference group, PAL: Physical activity level

10.1371/journal.pone.0160205.t004

###### Flow mediated dilation in men according to self-reported use of tobacco and peak oxygen uptake.

![](pone.0160205.t004){#pone.0160205.t004g}

                          N     Unadjusted   Model 1   Model 2                                       
  ----------------------- ----- ------------ --------- --------------- ------- ------------- ------- -------------
  **No smoke or snuff**   l     High         488       4.57            Ref.    \-            Ref.    \-
  Low                     349   4.57         0.02      -0.50, 0.55     0.03    -0.50, 0.55           
  **Smokers**                   High         148       4.46            -0.16   -0.85, 0.54   -0.14   -0.84, 0.56
  Low                     283   4.32         -0.26     -0.81, 0.30     -0.18   -0.75, 0.39           
  **Snuff users**               High         120       4.53            -0.19   -0.95, 0.57   -0.19   -0.96, 0.57
  Low                     105   3.86         -0.81     -1.61, -0.003   -0.74   -1.55, 0.07           

Model 1: adjusted for age; Model 2: adjusted for age, education and income; N: number of participants; FMD: Flow mediated dilation, %; 95% CI: 95% confidence interval, Ref.; Reference group

The lowest FMD (3.51%, 1.86, 5.15) was observed among the few men (n = 21) who used both smoking tobacco and snuff.

There were no difference in FMD between fit non- tobacco users (reference group) versus low fit non-tobacco users (0.03%, -0.50, 0.55, [Table 4](#pone.0160205.t004){ref-type="table"}), or those within recommended (active) versus below recommended (inactive) level of physical activity (-0.16%, 0.73, 0.40, [Table 3](#pone.0160205.t003){ref-type="table"}).

Discussion {#sec019}
==========

Few studies have examined the association between snuff-use and endothelial function, which is an early marker of cardiovascular risk that may emerge several years prior to clinical signs of disease.

Our data confirm the characteristics of the typical snuff user: younger, more fit, higher education, higher income and a more healthy diet compared to smokers \[[@pone.0160205.ref008]\], i.e. similar to non-users. Despite this FMD was lower in snuff users than in non-users and similar to smokers; and this trend was consistent even after adjustment for age and socio-economic status. The same trend revealed that unfit snuff users had even lower FMD compared to either smokers or non-users.

Our findings concur with smaller studies in young and healthy subjects, indicating an association between snuff use and impaired endothelial function \[[@pone.0160205.ref065],[@pone.0160205.ref066]\]. Our study measured FMD in 1 592 participants after a period of at least 4 hours of fasting, while one of few and smaller studies on endothelial function measured as FMD were performed in 20 healthy middle-aged snuff users (in which ten did a cross-over)\[[@pone.0160205.ref024]\]; FMD measured 20 and 35 minutes after the administration of 1 gram snuff or placebo showed impaired FMD after snuff-administration. In the other a cross-sectional study of FMD was performed on seventeen apparently healthy volunteers \[[@pone.0160205.ref066]\] measuring FMD in three groups: 1; smoking for more than 1 year and at least 10 cigarettes/day, 2; using at least two containers of snuff/week, or 3; not using any tobacco product. In that study, brachial artery FMD was significantly impaired in snuff-users and cigarette smokers compared with non-users. Thus, snuff seems to have a negative acute effect and a negative chronic effect on FMD.

Previous studies are not conclusive regarding the association between snuff use and future risk of cardiovascular disease, though some studies indicate an association \[[@pone.0160205.ref067],[@pone.0160205.ref068]\]. For example, the Atherosclerosis Risk in Communities study found a 1.3 fold higher incidence of cardiovascular disease in oral tobacco users compared to non-users \[[@pone.0160205.ref069]\]. In contrast, another study comparing previous snuff-use in men with myocardial infarction to men without myocardial infarction found no increased risk of MI in snuff-users. However, a limitation of that study is that it did not match the control subjects for age or other confounders \[[@pone.0160205.ref070]\].

A study from 1992 suggested that effects of snuff depend on the user's age and level of physical activity \[[@pone.0160205.ref071]\]. In our study, lower age in snuff-users had no positive association with FMD unless combined with high aerobic capacity or high physical activity level. This was an unexpected finding because of the known inverse association between age and FMD \[[@pone.0160205.ref019]\]. Exercise is known to improve endothelial function in a variety of inflammatory conditions known to cause endothelial dysfunction \[[@pone.0160205.ref072],[@pone.0160205.ref073]\], including aging \[[@pone.0160205.ref074]\]. Independent on modality, exercise enhances nitric oxide bioavailability, thereby improving endothelial function \[[@pone.0160205.ref075]\]. Exercise reduces blood pressure and decreases resting heart rate. It also alters muscle sympathetic nerve activity \[[@pone.0160205.ref076]\], thereby blunting the stress response triggered by snuff \[[@pone.0160205.ref077]\]. Regular physical activity diminishes some of these negative effects, irrespective of whether they result from autonomic effects \[[@pone.0160205.ref025],[@pone.0160205.ref078],[@pone.0160205.ref079]\] or from direct effects on endothelial cells \[[@pone.0160205.ref065],[@pone.0160205.ref080]\].

The interaction test for physical activity with tobacco groups was not significant in our study; nevertheless, there was a difference between FMD in snuff users with high versus low aerobic capacity ([Table 4](#pone.0160205.t004){ref-type="table"}) and a trend between tobacco groups ([Table 2](#pone.0160205.t002){ref-type="table"}). The observation that the lowest FMD occurred in men who used both snuff and smoking tobacco, increases suspicion that snuff adds a negative effect on FMD even in smokers ([Table 2](#pone.0160205.t002){ref-type="table"}).

We have previously shown a significant association between systolic blood pressure and endothelial function \[[@pone.0160205.ref061]\]. Snuff use is associated with increased heart rate and blood pressure \[[@pone.0160205.ref077],[@pone.0160205.ref081]\] and with decreased diastolic function \[[@pone.0160205.ref082]\]. Over time, increased blood pressure and decreased diastolic heart function could explain an association between snuff use and future heart failure \[[@pone.0160205.ref078]\]. Low FMD may therefore be an early warning-sign, heralding risk of future cardiovascular disease and indicating that inactive snuff-using men might be at an increased risk.

Strengths and Limitations {#sec020}
=========================

The strength of the present study is a large sample size including 1 592 men over a wide age range and directly measured flow mediated dilation. All participants were apparently healthy, without medications and disease conditions known to influence endothelial function. Still, we detected reduced endothelial function in snuff users, especially in physically inactive participants. The cross-sectional design did not allow for conclusions about causality in the associations between tobacco use and endothelial function. Tobacco use and physical activity status were self-reported, possibly involving a risk of misclassification that may have confounded the observed associations.

The self-selection of participants from the healthiest part of the population together with the exclusion of all participants with established cardiovascular disease may have concealed the effects of tobacco use, both snuff and smoking tobacco.

Conclusions {#sec021}
===========

In our study snuff-users had a clear tendency towards lower endothelial function compared to non-users, and were no better than in smokers, despite younger age and a more favourable cardiovascular risk profile. Inactive snuff-using men had lower endothelial function than their physically active counterparts, indicating that physical activity and cardiorespiratory fitness modified the effect of snuff on endothelial function. Longitudinal studies are needed to further explore the role of reduced endothelial function as a link between snuff use and future cardiovascular disease.
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